[5-min read] Oregon Psilocybin Services’ first study could make sessions more affordable.
[5-min read] Q&A with Clementine Kruczynski, Researcher & Educator
[5-min read] Study shows doctors vastly overestimate their psychedelic knowledge.
[4-min read] Q&A with L. Alison McInnes, Psychiatrist & VP
[5-min read] Cybin's Phase 2 depression trial achieves a 100% response rate.
[5-min read] Q&A with Kat Murti, Activist & Director
[5-min read] Pilot study shows psilocybin is safe and effective for vets with treatment-resistant depression.
[5-min read] Q&A with Niko Skievaski, Cofounder & CEO
[5-min read] Massachusetts votes 'no' on Question 4.
[6-min read] Q&A with Kathryn Tucker, Attorney & Director
[5-min read] Study shows antidepressants don't reduce psilocybin's effects.
[5-min read] Q&A with Jay & Cory Fiset, Certified Psychedelic Guides
